INSM Still a Net Net StockAfter a full quarter, INSM still remains as a net net selling below liquidation prices despite the market run up during October.
My initial cost basis of Insmed was at $0.86 based on a liquidation value of $0.91 at the time and now with prices in the mid 70c range, a look at the financial statements will provide a good indication of whether it will be worthwhile to double down on my existing small position or just hold onto it until more information breaks out.
Q3 Recent DevelopmentsIn my initial stock analysis of INSM, I stated my concern the company may easily burn through its cash received from the sale of its follow-on biologics (FOB) to Merck. I’ll get to the detailed numbers in later.
On the conference call, there was no Q&A session but a lot of the topics that people would have obviously asked were addressed. The most interesting point to note was that the board mentioned a merger or reverse merger.
This is something more similar to the impression I received in my initial analysis. INSM is basically running like a shell company. Lots of cash, a single product but no way to leverage it to its potential in its current state.
Since the company is looking to increase “shareholder value” a buyout is unlikely as current prices does not offer much shareholder value at all. It also seems like the board is more interested in continuing the operations of the company in some form or other.
I could endlessly continue speculating whether the company will merge or sell itself but that isn’t what’s important. Analyzing the financial statements to determine whether I can maintain my position is more important. The undergoing strategic review and results will come, it’s just a matter of time.
INSM Financial Statement AnalysisSince INSM has changed dramatically since one year ago, it’s pointless to compare with the previous years. Right now, the focus has to be on quarter versus quarter.
Income Statement Analysis(Click for larger version)
- Since the company’s only product, IPLEX, is being conserved for existing ALS patients, revenues decreased.
- SG&A is still fairly high due to the legal fees but due to external finance, legal and consulting services with the ongoing strategic review.
- Lower R&D expense now that FOB has gone to Merck.
- Interest income would be a low earnings quality in a normal company but for INSM, consistent interest income is a must. Increase is good.
Balance Sheet Analysis
- While accounts receivables and prepaid expenses went up, the big increase in percentage is because the numbers are fairly small so any small change will seem big. Compare this to the amount of decrease in liabilities.
- Overall, liabilities decreased 22% compared to the previous quarter so the current management has been doing a good job.
- Accoutns payable is down 18%
- Payroll liabilities down 59% now that there are only 15 full time employees
- Big reduction of income taxes. Probably due to the lack of revenue from now on.
Cash Flow Statement Analysis
When looking at the cash flow statement, keep in mind that the numbers are for the past 6months and 9months total cash flows. These numbers are not stated value except for certain items.
- No warning signs in the cash flow statement. The cash burn seems to be steady at around $1m per quarter. i.e. at this rate, the company can basically keep the company going as it is for the next 110 quarters, which is 27 years. But that’s just a hypothetical number. Either way, I know INSM can stick around for a long time without going bankrupt.
- The only reason why the cash at the end of period is reduced is because the company purchased more short term investments. As long as they are safe investments, I’m fine with it.
INSM Stock Price Calculation
INSM’s current stock price is still below net net working capital by a decent amount. I still believe it to be very undervalued.
There is no point in running the discounted cash flow spreadsheet because I have to view INSM as a quarter by quarter basis. No reason to try and project cash flows. The same reason goes for the Benjamin Graham spreadsheet.
However, I can use an EPV valuation because the valuation technique looks at a snapshot of the company’s value at a specific given time.
(Click to enlarge)
With a quick earnings power value, the value comes out to $1.40.
Considering all the numbers and the current situation of the company, I was quite glad that the company is operating better than I expected. While the company is losing money, it is being offset by reductions in expenses as the business continues to wind down. While a buyout isn’t as likely, any good news, however small, should send INSM back to shareholder value recovery.
The current valuation is very cheap compared to even the worst distressed situation so there is plenty of margin of safety.
INSM is still a small part of my portfolio but I doubled my position after earnings and am considering building a larger position.
DisclosureI own shares at the time of writing.